FINNISH NAT PUBLIC HEALTH has a total of 13 patent applications. Its first patent ever was published in 1990. It filed its patents most often in Australia, United States and EPO (European Patent Office). Its main competitors in its focus markets biotechnology and pharmaceuticals are GAMMADELTA THERAPEUTICS LTD, SHANGHAI CELL THERAPY RES INST and GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | United States | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | Israel | 1 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Sarvas Matti | 9 |
#2 | Puohiniemi Ritvaleena | 5 |
#3 | Muttilainen Susanna | 5 |
#4 | Butcher Sarah | 5 |
#5 | Runeberg-Nyman Kate | 5 |
#6 | Kontinen Vesa | 4 |
#7 | Nurminen-Kalliokoski Marjatta | 4 |
#8 | Wahlstroem Eva | 3 |
#9 | Idaenpaeaen-Heikkilae Ilona | 3 |
#10 | Palva Ilkka | 3 |
Publication | Filing date | Title |
---|---|---|
US5945278A | Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria | |
AU6142694A | Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria | |
US5380653A | Expression vectors and methods for intracellular protein production in bascillus | |
IL98727D0 | Production of outer membrane proteins in gram-positive bacteria and recovery of protective epitopes | |
AU5034490A | Novel expression vectors and methods for intracellular protein production |